Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 6/20 | 0.33 |
| ▸ | CA12 | O43570 | 5/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 1/20 | 0.30 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6734858 | 0.86 | CYP2A6 (0.56) | CYP2A6CA2CA12TPSAB1PTPRC | |
| SCHEMBL12093628 | 0.83 | CYP2A6 (0.40) | CYP2A6MRGPRX4OPRM1OPRK1CA2 | |
| SCHEMBL29469339 | 0.83 | CYP2A6 (0.43) | CYP2A6MRGPRX4OPRM1OPRK1CA2 | |
| SCHEMBL7247231 | 0.73 | CYP2A6 (0.43) | CYP2A6MRGPRX4OPRM1OPRK1TPSAB1 | |
| SCHEMBL7213512 | 0.73 | MEN1 (0.38) | CYP2A6CA2CA12 | |
| SCHEMBL25270499 | 0.73 | ALDH1A1 (0.35) | CYP2A6MRGPRX4CA2CA12TPSAB1 | |
| SCHEMBL29833385 | 0.73 | CYP2A6 (0.43) | CYP2A6MRGPRX4OPRM1OPRK1TPSAB1 | |
| SCHEMBL6734101 | 0.72 | CA2 (0.34) | CYP2A6MRGPRX4CA2CA12PTPRC | |
| SCHEMBL8058490 | 0.72 | CYP2A6 (0.46) | CYP2A6MRGPRX4OPRM1OPRK1PTPRC | |
| SCHEMBL154793 | 0.72 | CYP2A6 (0.47) | CYP2A6MRGPRX4OPRM1OPRK1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | disclosed |
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | US | disclosed |
| EP-1244616-A1 | (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SmithKline Beecham plc (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047874-A1 | (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | CD40, CD22, CD2 | CYP2A6 392/4885MRGPRX4 2978/4885OPRM1 1101/4885 |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | CYP2A6 552/4885MRGPRX4 3157/4885OPRM1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.